Health & Fitness:Medicine
Nuvothera Launches Next-Gen, Super-Micronized Turmeric Supplement
Art Clapp, Founder & CEO of Nuvothera, a Fort Worth, TX-based biotech company formed by seasoned dermatology pharmaceutical executives with the mission of developing novel OTC products for chronic, difficult-to-treat skin diseases such as psoriasis joins eHealth Radio and the Dermatology and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Art Clapp discuss the following:
Art Clapp is Founder & CEO of Nuvothera, a Fort Worth, TX-based biotech company formed by seasoned dermatology pharmaceutical executives with the mission of developing novel OTC products for chronic, difficult-to-treat skin diseases such as psoriasis. Nuvothera’s products incorporate natural botanical ingredients and use the latest in scientific knowledge and evidence-based research. Currently, the company has two products in its portfolio, both available via the company website and on Amazon: Prosoria™ Daily Psoriasis Treatment System and Nuvothera™ Super-Micronized™ Turmeric Curcumin. Both dermatologists (MDs) and scientists (PhDs) were involved in developing these products, which are dermatology and clinically tested and proven. In 2018, Art was named Entrepeneur of the Year by the Fort Worth Business Press and Nuvothera won the Tech FW (Fort Worth) Impact Award for a product that has the potential to impact our world.
Art has three decades of experience in pharmaceuticals managing US and international pharma markets in licensing, acquisitions, technology assessment, product development, commercialization, Rx and OTC product marketing, strategic planning, portfolio and product life-cycle management, and delivery systems.
Prior to founding Nuvothera, Art spent almost two decades at Galderma in Pharmaceutical Marketing and Business development roles Fort Worth, TX and in Paris, France.
He also spent thirteen years in Sales and Product managemen at Purdue Pharma in Norwalk, CT.
It is Free